Skip to content

Study · Non-randomized trial · n = 551 · 2006

10 results

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM

Diabetes, obesity & metabolism1 Jul 2006Cited by 308 (Europe PMC)

PMID16776751 (opens in a new tab)DOI10.1111/j.1463-1326.2006.00602.x (opens in a new tab)PepBankPUB-16776751
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, exenatide reduced body weight by 2.1 kg from baseline at week 30.

    In plain wordsExenatide lowered body weight by 2.1 kg from baseline at week 30.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight change at week 30
    Study

    n = 314

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    Body weight change from baseline at week 30
    −2.1 kg
    week 30, 314 patients

    Source sentences

    Summary
    At week 30, exenatide reduced body weight (a secondary endpoint) from baseline (-2.1 +/- 0.2 kg), with progressive reduction at week 82 (-4.4 +/- 0.3 kg).
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes completing treatment, exenatide reduced weight by 4.4 kg from baseline at week 82.

    In plain wordsAmong treatment completers, exenatide lowered weight by 4.4 kg from baseline at week 82.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight change at week 82
    Study

    n = 314

    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Measurements

    Body weight change from baseline at week 82
    −4.4 kg
    week 82, completers

    Source sentences

    Summary
    At week 30, exenatide reduced body weight (a secondary endpoint) from baseline (-2.1 +/- 0.2 kg), with progressive reduction at week 82 (-4.4 +/- 0.3 kg).
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  3. 03HumanNon-randomized trialEfficacy outcome

    In the intent-to-treat population with type 2 diabetes, exenatide reduced A1C by 0.8% from baseline at week 82.

    In plain wordsIn the intent-to-treat analysis, exenatide lowered A1C by 0.8% from baseline at week 82.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseIntent-to-treat A1C change
    Study

    n = 551

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Measurements

    A1C change from baseline at week 82
    −0.8%
    intent-to-treat population, week 82

    Source sentences

    Summary
    Similar results were observed for the intent-to-treat population (n = 551), with reductions in A1C and weight at week 82 of -0.8 +/- 0.1% and -3.5 +/- 0.2 kg respectively.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  4. 04HumanNon-randomized trialEfficacy outcome

    In the intent-to-treat population with type 2 diabetes, exenatide reduced weight by 3.5 kg from baseline at week 82.

    In plain wordsIn the intent-to-treat analysis, exenatide lowered weight by 3.5 kg from baseline at week 82.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseIntent-to-treat weight change
    Study

    n = 551

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Measurements

    Body weight change from baseline at week 82
    −3.5 kg
    intent-to-treat population, week 82

    Source sentences

    Summary
    Similar results were observed for the intent-to-treat population (n = 551), with reductions in A1C and weight at week 82 of -0.8 +/- 0.1% and -3.5 +/- 0.2 kg respectively.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes, exenatide reduced A1C by 0.9% from baseline at week 30.

    In plain wordsExenatide lowered A1C by 0.9% from baseline at week 30.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseA1C change at week 30
    Study

    n = 314

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 30 weeksAs given in this study (human).

    Measurements

    A1C change from baseline at week 30
    −0.9%
    week 30, 314 patients

    Source sentences

    Summary
    Reduction in A1C from baseline to week 30 [-0.9 +/- 0.1% (mean +/- SE)] was sustained to week 82 (-1.1 +/- 0.1%), with 48% of patients achieving A1C < or = 7% at week 82.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes completing treatment, exenatide reduced A1C by 1.1% from baseline at week 82.

    In plain wordsAmong treatment completers, exenatide lowered A1C by 1.1% from baseline at week 82.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseA1C change at week 82
    Study

    n = 314

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Measurements

    A1C change from baseline at week 82
    −1.1%
    week 82, completers

    Source sentences

    Summary
    Reduction in A1C from baseline to week 30 [-0.9 +/- 0.1% (mean +/- SE)] was sustained to week 82 (-1.1 +/- 0.1%), with 48% of patients achieving A1C < or = 7% at week 82.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  7. 07HumanNon-randomized trialEfficacy outcome

    At week 82, 48% of exenatide-treated completers achieved A1C at or below 7%.

    In plain wordsAt week 82, 48% of exenatide-treated completers reached A1C of 7% or less.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableA1C target attainment
    Study

    n = 314

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Measurements

    Patients achieving A1C <= 7%
    48%
    week 82, completers

    Source sentences

    Summary
    Reduction in A1C from baseline to week 30 [-0.9 +/- 0.1% (mean +/- SE)] was sustained to week 82 (-1.1 +/- 0.1%), with 48% of patients achieving A1C < or = 7% at week 82.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  8. 08HumanNon-randomized trialEfficacy outcome

    In exenatide-treated completers, some unspecified cardiovascular risk factors improved significantly at week 82.

    In plain wordsSome unspecified heart and blood vessel risk factors improved in exenatide-treated completers at week 82.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableCardiovascular risk factors
    Study

    n = 314

    Outcome group
    Cardiometabolic risk factors · Cardiovascular
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Source sentences

    Summary
    The 82-week completer cohort showed statistically significant improvement in some cardiovascular risk factors.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  9. 09HumanNon-randomized trialSafety outcome

    Nausea was among the most frequent adverse events during exenatide treatment and was generally mild to moderate.

    In plain wordsNausea was a frequent side effect during exenatide treatment and was generally mild to moderate.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Source sentences

    Summary
    The most frequent adverse events were generally mild-to-moderate nausea and hypoglycaemia.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.
  10. 10HumanNon-randomized trialSafety outcome

    Hypoglycaemia was among the most frequent adverse events during exenatide treatment and was generally mild to moderate.

    In plain wordsLow blood sugar was a frequent side effect during exenatide treatment and was generally mild to moderate.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableHypoglycaemia
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 82 weeksAs given in this study (human).

    Source sentences

    Summary
    The most frequent adverse events were generally mild-to-moderate nausea and hypoglycaemia.
    2 context sentences
    Summary · context
    This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total.
    Summary · context
    Patients continued their SU and/or MET regimens throughout.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial pageClinicalTrials.govUpdated 5 May 2016
CompletedPhase 3NCT00111540

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

AstraZenecan = 456Nov 2002 to Sept 2006

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 23 Feb 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.